Drugs / dual-targeting BCMA-CD19 CAR-T cell therapy
dual-targeting BCMA-CD19 CAR-T cell therapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07003555 | May 2025 → May 2027 expected | refractory plasma cell neoplasm | Beijing GoBroad Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dual-targeting BCMA-CD19 CAR-T cell therapy | “Patients receive dual-targeting BCMA-CD19 CAR-T cell therapy” NCT07003555 ↗ |
| Modality | Cell therapy | “dual-targeting BCMA-CD19 CAR-T cell therapy” NCT07003555 ↗ |